Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An eosinophilic esophagitis that starts in childhood.
Biomarker and diagnostic research for childhood eosinophilic esophagitis has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
185 publications have been identified in PubMed for childhood eosinophilic esophagitis. Research spans Review / Meta-Analysis (45%), Epidemiology / Natural History (17%), and Basic Science / Preclinical (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 83 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:32 AM UTC
Disease patterns and progression | 31 | 17% |
Laboratory research | 21 | 11% |
Clinical study results | 18 | 10% |
Other research | 11 | 6% |
Testing and diagnosis research | 10 | 5% |
Patient case studies | 7 | 4% |
New treatment approaches | 4 | 2% |
Tseng WY (2026). [PMID: 42156272](https://pubmed.ncbi.nlm.nih.gov/42156272/). *Pediatr Neonatol*. [Epidemiology / Natural History]
Hiremath G (2026). [PMID: 42258787](https://pubmed.ncbi.nlm.nih.gov/42258787/). *Dis Esophagus*. [Epidemiology / Natural History]
Demidova A (2026). [PMID: 41974646](https://pubmed.ncbi.nlm.nih.gov/41974646/). *Clin Exp Allergy*. [Review / Meta-Analysis]
Kennedy KV (2026). [PMID: 40819800](https://pubmed.ncbi.nlm.nih.gov/40819800/). *Gastroenterology*. [Epidemiology / Natural History]
Gil P (2026). [PMID: 41165056](https://pubmed.ncbi.nlm.nih.gov/41165056/). *J Pediatr Gastroenterol Nutr*. [Epidemiology / Natural History]
Isa HM (2026). [PMID: 41905826](https://pubmed.ncbi.nlm.nih.gov/41905826/). *Pediatr Neonatol*. [Epidemiology / Natural History]
Renzo S (2026). [PMID: 41257441](https://pubmed.ncbi.nlm.nih.gov/41257441/). *J Pediatr Gastroenterol Nutr*. [Epidemiology / Natural History]
Patel RH (2026). [PMID: 42285365](https://pubmed.ncbi.nlm.nih.gov/42285365/). *J Allergy Clin Immunol*. [Diagnostic / Biomarker]
Aggoun Zioueche N (2026). [PMID: 41791995](https://pubmed.ncbi.nlm.nih.gov/41791995/). *Arch Pediatr*. [Review / Meta-Analysis]
Sessions J (2026). [PMID: 41764702](https://pubmed.ncbi.nlm.nih.gov/41764702/). *Paediatr Drugs*. [Review / Meta-Analysis]
AI-curated news mentioning childhood eosinophilic esophagitis
Updated Aug 27, 2026
Tezspire shows positive results in a study for eosinophilic esophagitis, potentially becoming its third approved indication. This development could significantly expand its market potential for AstraZeneca and Amgen.
A new study explores the pathophysiology and clinical overlap between eosinophilic esophagitis and laryngeal manifestations, highlighting diagnostic challenges. This research may inform better diagnostic and treatment strategies for affected patients.
A case report highlights the conservative management of gastroesophageal junction perforation caused by eosinophilic esophagitis. This study contributes to the understanding of treatment options for this rare condition.
The DUPEOETALY study demonstrates the long-term effectiveness of dupilumab in treating eosinophilic esophagitis. This research provides valuable insights into the sustained benefits of this therapy for patients with this rare condition.